CAESAREA, Israel, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (TASE: ITMR), a company that develops, manufactures, and markets non-invasive diagnostic medical devices for sleep-apnea with a focus on the cardiology market, today announced the release of the 2019 Fee Schedule from the U.S. Centers for Medicare & Medicaid Services (CMS) that should support broad use of its WatchPAT technology.
WatchPAT is the only product in the market today that uses Peripheral Arterial Tone (PAT) technology, providing cardiologists and sleep physicians in the United States with accurate sleep diagnosis that enhances clinical decision-making. The Company estimates that WatchPAT accounted for approximately 15% of the home sleep tests in the United States in 2017.
Gilad Glick, CEO of Itamar Medical said, “We believe that the new CMS Fee Schedule validates the clinical value of our sleep tests for patients and may significantly advance utilization of our innovative sleep tests in the U.S market. It also reflects growing awareness of deploying home sleep apnea testing and sleep apnea management as essential components of the cardiology care pathway.”
For more information about the CMS decision visit Itamar Medical Website www.itamar-medical.com
About Itamar Medical Ltd.
Itamar Medical Ltd. is a public company traded on the Tel Aviv Stock Exchange and has been operating since its inception in the research and development of non-invasive medical devices for diagnosis of respiratory disorders. In recent year the company has focused on leading the integration of sleep apnea management into the cardiac care pathway with its Total Sleep Solution.
Investor Contact:
David Carey
212-867-1768
dcarey@lazarpartners.com